Electronic Clinical Surveillance to Measure and Improve Safety in Ambulatory Care

用于衡量和提高门诊护理安全性的电子临床监测

基本信息

  • 批准号:
    9143145
  • 负责人:
  • 金额:
    $ 49.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-09-30 至 2018-07-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Efforts to improve patient safety have largely focused on inpatient settings, despite the fact that there are an estimated one billion outpatient visits each year in the United States. We propose here to study the incidence of three types of medical errors and the underlying factors that contribute to them within the ambulatory care settings of a large, diverse integrated delivery system. Specifically, we will study: diagnostic error (delayed diagnosis of kidney disease), treatment error (the use of contraindicated medications among patients with a history of falls), and preventive error (lack of annual monitoring for patients on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)). There are unique challenges to identifying and intervening on care gaps in ambulatory care settings. Care is often diffuse, involving multiple providers over long time periods. There is an inherent delay in the availability of certain key pieces of information (e.g., laboratory results). Additionally, some care gaps only become identifiable weeks or months after their causes (e.g., failure to follow-up an abnormal test result is apparent only afte the usual time for follow-up has elapsed). Further, a greater number of healthy patients present with similar symptoms as patients who have serious health conditions, which may contribute to missed diagnoses or delayed follow-up care. And, patients play a greater role in care quality within ambulatory settings. Although electronic health records have been found to be insufficient for addressing care gaps themselves, they offer an efficient way to study medical errors in ambulatory settings. This is particularly true within integrated delivery systems, where processes of care across different settings and long time periods are comprehensively documented and readily linked. We propose to determine the incidence (Aim 1) and risk factors (Aim 2) for 3 types of medical errors within Kaiser Permanente Southern California (KPSC) from 2010-2015. KPSC serves a diverse population of 4 million current members, seen by over 6,000 providers in an estimated 12 million annual outpatient encounters. We will leverage KPSC's advanced electronic health record and innovative program in outpatient safety to efficiently identify cohorts of at-risk patients and to estimate the incidence of, and risk factors for, medica errors using Poisson regression. We also will generate insights into the causes of, and potential interventions for, medical errors in ambulatory care (Aim 3) through one-on-one interviews of patients and providers (n=90) and via input from an external Advisory Board (n=5). This study will generate novel information on the incidence and risk factors for 3 types of medical errors in ambulatory care settings. Our long-term goal is to contribute to meaningful patient care improvements through the use of electronic health data. This study represents a first step toward that goal, as it will generate information to inform future research and interventions to improve ambulatory care safety.
 描述(由申请人提供):改善患者安全性的努力主要集中在住院环境中,尽管美国每年估计有10亿次门诊就诊。我们建议在这里研究三种类型的医疗差错的发生率和潜在的因素,有助于他们在一个大型的,多样化的综合交付系统的门诊护理设置。具体而言,我们将研究:诊断错误(肾脏疾病的延迟诊断)、治疗错误(在有福尔斯病史的患者中使用禁忌药物)和预防错误(缺乏对血管紧张素转换酶(ACE)抑制剂或血管紧张素受体阻滞剂(ARB)患者的年度监测)。有独特的挑战,以确定和干预的护理差距在门诊护理设置。护理往往是分散的,涉及多个提供者在很长一段时间。某些关键信息的可用性存在固有的延迟(例如,实验室结果)。此外,一些护理差距只有在其原因发生后的几周或几个月才能确定(例如,只有在通常的随访时间过去之后,才能明显看出对异常测试结果的随访失败)。此外,更多的健康患者出现与患有严重健康状况的患者相似的症状,这可能导致漏诊或延迟随访。而且,患者在门诊环境中的护理质量方面发挥着更大的作用。虽然电子健康记录已被发现不足以解决护理差距本身,他们提供了一个有效的方法来研究医疗差错在门诊设置。在综合交付系统中尤其如此,其中不同环境和长时间段的护理流程得到了全面记录并易于链接。我们建议确定2010-2015年Kaiser Permanente Southern加州(KPSC)内3种医疗差错的发生率(目标1)和风险因素(目标2)。KPSC为400万现有会员的多样化人口提供服务,估计每年有1200万门诊病人,有6,000多名提供者。我们将利用KPSC先进的电子健康记录和门诊安全创新计划,有效地识别高危患者队列,并使用泊松回归估计医疗错误的发生率和风险因素。我们还将通过对患者和提供者(n=90)的一对一访谈以及外部咨询委员会(n=5)的输入,深入了解门诊医疗差错(目标3)的原因和潜在干预措施。本研究将产生关于门诊护理环境中3种类型医疗差错的发生率和风险因素的新信息。我们的长期目标是通过使用电子健康数据为有意义的患者护理改善做出贡献。这项研究代表了实现这一目标的第一步,因为它将产生信息,为未来的研究和干预提供信息,以提高门诊护理安全性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kim N Danforth其他文献

Kim N Danforth的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kim N Danforth', 18)}}的其他基金

Electronic Clinical Surveillance to Measure and Improve Safety in Ambulatory Care
用于衡量和提高门诊护理安全性的电子临床监测
  • 批准号:
    9060128
  • 财政年份:
    2015
  • 资助金额:
    $ 49.78万
  • 项目类别:
Trends and Disparities in Bladder Cancer Treatment
膀胱癌治疗的趋势和差异
  • 批准号:
    8692201
  • 财政年份:
    2014
  • 资助金额:
    $ 49.78万
  • 项目类别:
Trends and Disparities in Bladder Cancer Treatment
膀胱癌治疗的趋势和差异
  • 批准号:
    8930089
  • 财政年份:
    2014
  • 资助金额:
    $ 49.78万
  • 项目类别:

相似国自然基金

Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

NSF/FDA: Towards an active surveillance framework to detect AI/ML-enabled Software as a Medical Device (SaMD) data and performance drift in clinical flow
NSF/FDA:建立主动监测框架,以检测支持 AI/ML 的软件即医疗设备 (SaMD) 数据和临床流程中的性能漂移
  • 批准号:
    2326034
  • 财政年份:
    2023
  • 资助金额:
    $ 49.78万
  • 项目类别:
    Standard Grant
Active surveillance vs definitive local therapy for patients showing clinical complete response following neoadjuvant cisplatin-based chemotherapy
对基于顺铂的新辅助化疗后表现出临床完全缓解的患者进行主动监测与明确的局部治疗
  • 批准号:
    487681
  • 财政年份:
    2023
  • 资助金额:
    $ 49.78万
  • 项目类别:
    Operating Grants
Mapping the pathway of blood and information collected from HIV-positive people in a clinical setting: implications for public health surveillance, consent, and criminalization
绘制临床环境中从艾滋病毒阳性者身上收集的血液和信息的路径:对公共卫生监测、同意和刑事定罪的影响
  • 批准号:
    467746
  • 财政年份:
    2022
  • 资助金额:
    $ 49.78万
  • 项目类别:
    Operating Grants
A pilot clinical trial to evaluate the feasibility and acceptability of: A prospective, unblinded, randomized-controlled, multicenter biomarker intervention trial of a urinary CXCL10 clinical surveillance program in pediatric kidney transplant recipients
一项试点临床试验,旨在评估以下项目的可行性和可接受性:一项针对儿科肾移植受者尿液 CXCL10 临床监测项目的前瞻性、非盲式、随机对照、多中心生物标志物干预试验
  • 批准号:
    470654
  • 财政年份:
    2022
  • 资助金额:
    $ 49.78万
  • 项目类别:
    Operating Grants
Tsepamo Plus: Expanded Congenital Abnormalities Surveillance with an Emulated Clinical Trial to Evaluate Weight Impact on Birth Outcomes for Newer ART Regimens
Tsepamo Plus:通过模拟临床试验扩大先天性异常监测,以评估体重对新 ART 治疗方案出生结果的影响
  • 批准号:
    10495244
  • 财政年份:
    2021
  • 资助金额:
    $ 49.78万
  • 项目类别:
Tsepamo Plus: Expanded Congenital Abnormalities Surveillance with an Emulated Clinical Trial to Evaluate Weight Impact on Birth Outcomes for Newer ART Regimens
Tsepamo Plus:通过模拟临床试验扩大先天性异常监测,以评估体重对新 ART 治疗方案出生结果的影响
  • 批准号:
    10381145
  • 财政年份:
    2021
  • 资助金额:
    $ 49.78万
  • 项目类别:
Leveraging deep learning and clinical notes for surveillance and prediction of intentional self-harm and suicide
利用深度学习和临床记录来监测和预测故意自残和自杀
  • 批准号:
    10330113
  • 财政年份:
    2021
  • 资助金额:
    $ 49.78万
  • 项目类别:
Tsepamo Plus: Expanded Congenital Abnormalities Surveillance with an Emulated Clinical Trial to Evaluate Weight Impact on Birth Outcomes for Newer ART Regimens
Tsepamo Plus:通过模拟临床试验扩大先天性异常监测,以评估体重对新 ART 治疗方案出生结果的影响
  • 批准号:
    10696260
  • 财政年份:
    2021
  • 资助金额:
    $ 49.78万
  • 项目类别:
COVID-19 Variant Supplement - Wastewater surveillance of SARS-COV2 to enable real-time clinical case-finding in Calgary
COVID-19 变异补充 - SARS-COV2 废水监测,以实现卡尔加里的实时临床病例发现
  • 批准号:
    443271
  • 财政年份:
    2021
  • 资助金额:
    $ 49.78万
  • 项目类别:
    Operating Grants
NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens (U01) Clinical Trials Not Allowed
NARMS 加强零售食品样本抗生素耐药性监测的合作协议计划 (U01) 不允许进行临床试验
  • 批准号:
    10170519
  • 财政年份:
    2020
  • 资助金额:
    $ 49.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了